It has been reported that nearly half of patients with VRL or PCNSL could be classified as MCD subtype (3, 4), and the BTK inhibitor ibrutinib results in an overall response rate of 80% in patients with MCD subtype of DLBCL (9). Here, BTK is linked to primary central nervous system lymphoma.